Rachel received her Honours Bachelor of Science at the University of Toronto with a major in Neuroscience and a double minor in Physiology and Sociology. She completed her undergraduate thesis in Dr. Herman Yeger’s laboratory where she investigated the role of TAS2R bitter taste receptors in cystic fibrosis lung disease. Rachel subsequently worked as a research assistant in the laboratory of Dr. Carol Westall, where she investigated Vigabatrin-attributed retinal toxicity in pediatric patients with infantile spasms.
Rachel joined Dr. Fehlings laboratory in May 2014 and is currently a graduate student at the Institute of Medical Science at the University of Toronto. Her research focuses on exploring the mechanisms underlying neural progenitor cell therapy in spinal cord injury and enhancing therapeutic potential through modulation of the cytotoxic lesional microenvironment.